Acrivon Therapeutics (NASDAQ:ACRV) Coverage Initiated at Cantor Fitzgerald

Cantor Fitzgerald assumed coverage on shares of Acrivon Therapeutics (NASDAQ:ACRV) in a report issued on Friday,Benzinga reports. The firm issued an overweight rating on the stock.

A number of other research analysts have also weighed in on ACRV. BMO Capital Markets dropped their price target on shares of Acrivon Therapeutics from $28.00 to $27.00 and set an “outperform” rating on the stock in a research report on Thursday, November 14th. KeyCorp began coverage on Acrivon Therapeutics in a research note on Friday. They issued an “overweight” rating on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and set a $22.00 price target on shares of Acrivon Therapeutics in a research report on Thursday, November 14th. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Acrivon Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $23.67.

Acrivon Therapeutics Stock Performance

Shares of NASDAQ:ACRV opened at $6.07 on Friday. The stock’s fifty day simple moving average is $6.34 and its two-hundred day simple moving average is $7.34. Acrivon Therapeutics has a 1-year low of $3.19 and a 1-year high of $11.90.

Institutional Investors Weigh In On Acrivon Therapeutics

Hedge funds have recently modified their holdings of the stock. Exome Asset Management LLC purchased a new stake in Acrivon Therapeutics in the third quarter worth $817,000. State Street Corp grew its stake in shares of Acrivon Therapeutics by 26.4% during the 3rd quarter. State Street Corp now owns 225,896 shares of the company’s stock worth $1,581,000 after acquiring an additional 47,233 shares during the period. JPMorgan Chase & Co. increased its holdings in Acrivon Therapeutics by 548.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 33,991 shares of the company’s stock worth $238,000 after acquiring an additional 28,748 shares during the last quarter. Barclays PLC raised its stake in Acrivon Therapeutics by 51.2% in the 3rd quarter. Barclays PLC now owns 33,306 shares of the company’s stock valued at $233,000 after acquiring an additional 11,273 shares during the period. Finally, Dimensional Fund Advisors LP purchased a new stake in Acrivon Therapeutics during the second quarter valued at about $58,000. Institutional investors own 71.62% of the company’s stock.

About Acrivon Therapeutics

Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.